• Valeant Pharmaceuticals International, Inc.
    Cataract/Anterior Segment, Comprehensive Ophthalmology, Cornea/External Disease, Refractive Mgmt/Intervention

    Bausch & Lomb says it received U.S. Food and Drug Administration clearance for an advanced swept-source OCT imaging system and updated software for its Victus femtosecond laser platform.

    “With the availability of the advanced OCT imaging and software enhancements, surgeons can monitor treatments in real-time and with exceptional clarity throughout entire procedures, providing even greater control and consistency to support outstanding surgical outcomes for their patients,” said Dr. Ari Kellen, executive vice president and company group chairman for Valeant, the parent company of Bausch & Lomb.

    With a redesigned interface, the company says the laser allows for faster, simpler customized treatment planning, while the new software and imaging system delivers auto-recognition of key landmarks in the eye, including the pupil, anterior capsule and posterior capsule, along with the capsule tilt compensation to maximize lens fragmentation.

    The company notes additional features include: 

    • Improved imaging speed and sensitivity compared to conventional time domain detection techniques with unprecedented responsive video frame rate.
    • High contrast, exceptional detail and clarity allow OCT-guided adjustment for all phases of cataract and corneal procedures during docking through planning and non-stop throughout treatment.
    • OCT-guided planning of up to two arcuate incisions independently configurable in diameter, depth, position and size with a magnified cross-sectional scan allowing depth adjustment of the incisions utilizing pachymetry.
    • Improved docking via high-contrast, live streaming OCT.